116th Congress Could Test Cosmetic Industry’s Commitment To Reg Reform, Preemption Viability

With Democrats in control of the House and New Jersey Rep. Frank Pallone in line for chair of the Energy & Commerce Committee, cosmetics regulatory reform legislation could receive even more attention in the 116th Congress than in the current session. The new climate could test how serious big business is about embracing large-scale changes as well as lawmakers’ openness to federal preemption. 

Washington DC Capitol dome detail with waving american flag

Democrats have firm control of the US House going into the 116th Congress, a change that promises to complicate cosmetics legislative reform efforts and potentially erode industry’s influence in negotiations.

Whether or not their midterm wins were indeed the much-anticipated “blue wave," which remains fodder for debate, Dems succeeded...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legislation

US House Passes ‘Do Not Flush’ Legislation For Non-Flushable Personal Care Wipes

 

The US House of Representatives passes legislation requiring manufacturers of non-flushable wet wipes to label products as ‘non-flushable," a move endorsed by the Personal Care Products Council.

California Legislators Advance Bill To Ban Plastic Glitter, Abrasive Microbeads In Personal Care

 
• By 

Lawmakers in California heeded calls from industry to change proposed legislation to avoid a wider ban on microplastics in personal care products.

House Bill Aims to ‘Modernize’ US FDA’s Review Process For Sunscreens

 

Four co-chairs of the House of Representatives’ Skin Cancer Caucus have introduced the Safe Sunscreen Standards Act to direct FDA to establish clearer, ‘more flexible’ standards for evaluating sunscreen ingredients.

House Appropriators’ $3.2Bn For FDA In FY 2026 Includes More Non-User Fee Funds Than Requested

 

A US House bill would give the FDA $33.1m more in budget authority than requested by the Trump Administration for fiscal year 2026. The measure was sent to the full House Appropriations committee on a party-line vote.

More from Policy & Regulation

FDA Urged To Issue Formaldehyde Rule As California Finds Non-Compliance With State Ban

 
• By 

Stakeholders are still waiting for the US FDA to issue its widely anticipated proposed rule to prohibit formaldehyde and formaldehyde releasers from hair smoothing or straightening products.

Cloudy Tariff Conditions Expected To Linger In US

 

White House announces president extends deadline he set in April for other countries to make new tariff deals from July 9 to Aug. 1, when the administration will start sending letters warning other countries that higher tariffs could take effect.

US FDA’s Tough Talk On Talc: Regulating In An Echo Chamber

 

An FDA “expert roundtable” on talc produced a new talking point on a potential drug safety risk, but the basis of that claim is difficult to determine.